A US government panel has urged regulators to approve a drug to treat low sexual desire in women, nicknamed the “female Viagra”.
The experts backed flibanserin, but said it must carry warnings about strong possible side effects including fainting and tiredness.
The final decision now moves to the US Food and Drug Administration (FDA).
The FDA has rejected the drug twice since 2010 but it usually follows the advice of its experts.
Women taking the drug reported between 0.5 and one more sexually satisfying event per month, results experts admitted were “modest”.
“But on the other hand, even modest results can make a lot of difference when you’re at a certain point in the clinical problem,” said Dr Julia Heiman of the Kinsey Institute at Indiana University.
No Comments